# Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer

> **NCT01665274** · PHASE2 · TERMINATED · sponsor: **Harbin Medical University** · enrollment: 15 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **PROCEDURE:** D2 resection

## Key facts

- **NCT ID:** NCT01665274
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2020-08
- **Final completion:** 2022-09
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** we are working on a larger similar multicenter cinical trials as a participant.so in order to avoid conflicts of interest, we have to suspended this project.
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01665274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01665274, "Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01665274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*